9 assets in Pheochromocytoma

Therapeutic assets addressing Pheochromocytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Pheochromocytoma	Cancer Research UK	P1/2	CCC (48)
htl0039732 capsules Pheochromocytoma	Cancer Research UK	P1/2	CCC (48)
Olaparib Pheochromocytoma	Fundación de investigación HM	P1/2	CC (47)
Oxodotreotide Pheochromocytoma	Fundación de investigación HM	P1/2	CC (47)
Autologous Anti-Cd19 Car-Expressing T Lymphocytes Pheochromocytoma	Anusha Kalbasi	P1	CC (43)
Cyclophosphamide Pheochromocytoma	Anusha Kalbasi	P1	CC (43)
Fludarabine Pheochromocytoma	Anusha Kalbasi	P1	CC (43)
Fludeoxyglucose Pheochromocytoma	Anusha Kalbasi	P1	CC (43)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells Pheochromocytoma	Anusha Kalbasi	P1	CC (43)